Clear All
11120 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00093-7639-41 00093-7639 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug 12, 2013 Jul 31, 2019 In Use
50242-0717-86 50242-0717 Cobimetinib Cotellic 20.0 mg/1 Chemotherapy MAPK/MEK Inhibitor BRAF Oral Nov 10, 2015 In Use
54868-5260-01 54868-5260 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jun 28, 2005 In Use
00781-3530-10 00781-3530 Cyclophosphamide Cyclophosphamide 2000.0 mg/20mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Apr 8, 2024 In Use
54868-5260-02 54868-5260 Capecitabine Xeloda 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Jun 28, 2005 In Use
10702-0361-99 10702-0361 Carmustine Carmustine Chemotherapy Alkylating Agent Nitrosourea Intravenous Mar 1, 2024 In Use
16714-0001-01 16714-0001 Doxorubicin hydrochloride Doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Mar 22, 2021 Mar 1, 2025 In Use
00143-9548-10 00143-9548 Doxorubicin Hydrochloride Adriamycin 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous May 1, 1996 In Use
16714-0676-01 16714-0676 Sunitinib malate Sunitinib malate 12.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR, KIT, RET, CSF Oral Feb 18, 2022 In Use
50419-0171-06 50419-0171 Regorafenib Stivarga 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl Oral May 1, 2021 In Use
16729-0118-38 16729-0118 Gemcitabine Hydrochloride Gemcitabine Hydrochloride 2.0 g/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug 31, 2011 In Use
16729-0131-30 16729-0131 FLUDARABINE FLUDARABINE PHOSPHATE 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Nov 22, 2022 In Use
16729-0223-61 16729-0223 temsirolimus Temsirolimus Chemotherapy Enzyme Inhibitor mTOR Intravenous Aug 13, 2018 In Use
16729-0244-38 16729-0244 Pemetrexed Pemetrexed 1.0 g/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 In Use
16729-0246-05 16729-0246 Mitomycin Mitomycin 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous May 3, 2013 Apr 30, 2023 No Longer Used
53964-0001-01 53964-0001 Thiotepa Tepadina 15.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical Jan 26, 2017 Aug 1, 2018 In Use
16729-0522-05 16729-0522 Pemetrexed disodium Pemetrexed 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sep 8, 2022 In Use
25021-0205-05 25021-0205 Fludarabine phosphate Fludarabine phosphate 50.0 mg/2mL Chemotherapy Antimetabolite Purine Analog Intravenous Feb 1, 2009 May 31, 2018 No Longer Used
25021-0206-06 25021-0206 Topotecan Hydrochloride Topotecan Hydrochloride 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Campothecin Analogs Intravenous Nov 28, 2010 Jun 30, 2017 No Longer Used
25021-0207-05 25021-0207 Doxorubicin Hydrochloride doxorubicin hydrochloride 2.0 mg/mL Chemotherapy Antitumor Antibiotic Anthracycline Intravenous Oct 31, 2013 Sep 30, 2020 No Longer Used
23155-0261-41 23155-0261 Carmustine BiCNU Chemotherapy Alkylating Agent Nitrosourea Intravenous Apr 4, 2013 Aug 31, 2022 No Longer Used
23155-0649-41 23155-0649 CARMUSTINE CARMUSTINE Chemotherapy Alkylating Agent Nitrosourea Intravenous Oct 1, 2019 In Use
16729-0267-65 16729-0267 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous May 30, 2013 In Use
62332-0678-10 62332-0678 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb 28, 2023 In Use
23155-0775-71 23155-0775 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Jun 15, 2022 Jun 15, 2022 No Longer Used

Found 11120 results — Export these results